Group 5 drugs for multidrug-resistant tuberculosis: Individual patient data meta-analysis

European Respiratory Journal

Volumn 49, Issue 1, 2017, Pages

  Fox, Greg J ^a   Benedetti, Andrea ^b   Cox, Helen ^c   Koh, Won Jung ^d   Viiklepp, Piret ^e   Ahuja, Shama ^f   Pasvol, Geoffrey ^g   Menzies, Dick ^a,b   Ahuja, S ^h   Ashkin, D ⁱ   Avendano M ^j   Banerjee, R ^k   Bauer, M ^l   Hollm Delgado, M G ^l   Pai, M ^l   Shah, L ^l   Bayona, J N ^m   Becerra, M ^n,o   Burgos, M ^p   Centis, R ^q   D'Ambrosio, L ^q   Migliori, G B ^q   Chan, E D ^r   Chiang, C Y ^s   De Lange, W C M ^t   Van Altena, R ^t   Van Der Werf, T S ^t   De Riemer, K ^u   Dung, N H ^v   Enarson, D ^w   Falzon, D ^q   Granich, R M ^q   Flanagan, K ^x   Flood, J ^y   Gandhi, N ^z   Garcia Garcia, L ^aa   Holtz, T H ^ab   Iseman, M ^ac   Strand, M J ^ac   Jarlsberg, L G ^ad   Royce, S ^ad   Keshavjee, S ⁿ   Kim, H R ⁿ   Mitnick, C D ⁿ   Lancaster, J ^ae   Van Der Walt, M ^ae   Lange, C ^af   Leimane, V ^ag   Riekstina, V ^ag   Leung, C C ^ah   Li, J ^ai   Narita, M ^aj   O'Riordan, P ^ak   Palmero, D ^al   Park, S K ^am   Pena, J ^an   Perez Guzman C ^ao   Ponce De Leon, A ^ap   Sifuentes Osornio, J ^ap   Quelapio, M I D ^aq   Tupasi, T E ^aq   Robert, J ^ar   Schaaf, H S ^as   Seung, K J ^at   Shin, S S ^at   Shim, T S ^au   Shiraishi, Y ^av   Sotgiu, G ^aw   Tabarsi, P ^ax   Vargas, M H ^ay   Westenhouse, J ^az   Yew, W W ^ba   Yim, J J ^bb   more..

^a UNIVERSITY OF SYDNEY   (Australia)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d Samsung Medical Center   (South Korea)

^e NATIONAL INSTITUTE FOR HEALTH DEVELOPMENT   (Estonia)

^f NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h Bureau of Tuberculosis   (United States)

ⁱ AG Holley Hospital   (United States)

^j UNIVERSITY OF TORONTO   (Canada)

^k MAYO CLINIC   (United States)

^l MCGILL UNIVERSITY   (Canada)

^m DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

ⁿ HARVARD MEDICAL SCHOOL   (United States)

^o PARTNERS IN HEALTH   (United States)

^p UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^q WORLD HEALTH ORGANIZATION   (Switzerland)

^r VETERANS AFFAIRS MEDICAL CENTER   (United States)

^s TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^t UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^u UNIVERSITY OF CALIFORNIA   (United States)

^v World Health Organization ^*  (Viet Nam)

^w INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^x MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^y CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^z ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^aa INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^ab Centers for Disease Control CDC Thailand Field Station   (Thailand)

^ac DEPARTMENT OF MEDICINE   (United States)

^ad UNIVERSITY OF CALIFORNIA   (United States)

^ae SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^af Tuberculosis Center Borstel   (Germany)

^ag Clinic of Tuberculosis and Lung Diseases   (Latvia)

^ah DEPARTMENT OF HEALTH   (Hong Kong)

^ai New York City Health and Mental Hygiene   (United States)

^aj UNIVERSITY OF WASHINGTON   (United States)

^ak Medical Centre   (United Kingdom)

^al HOSPITAL F J MUÑIZ   (Argentina)

^am TB Center   (South Korea)

^an UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^ao Instituto de Salud del Estado de Aguascalientes   (Mexico)

^ap INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^aq Tropical Disease Foundation   (Philippines)

^ar SORBONNE UNIVERSITÉ   (France)

^as UNIVERSITY OF STELLENBOSCH   (South Africa)

^at BRIGHAM AND WOMEN S HOSPITAL   (United States)

^au University of Ulsan College of Medicine   (South Korea)

^av Japan Anti Tuberculosis Association   (Japan)

^aw UNIVERSITY OF SASSARI   (Italy)

^ax SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^ay INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^az Center for Infectious Diseases   (United States)

^ba GRANTHAM HOSPITAL   (Hong Kong)

^bb Seoul National University   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CLARITHROMYCIN; CLOFAZIMINE; IMIPENEM; ISONIAZID; LINEZOLID; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TERIZIDONE; THIOACETAZONE; AMOXICILLIN; ISOXAZOLE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; DEATH; DRUG EFFICACY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROPENSITY SCORE; RELAPSE; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; COHORT ANALYSIS; COMBINATION DRUG THERAPY; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MULTIVARIATE ANALYSIS; STATISTICAL MODEL; YOUNG ADULT;

ADULT; AMOXICILLIN; ANTITUBERCULAR AGENTS; CLOFAZIMINE; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISOXAZOLES; LINEZOLID; LOGISTIC MODELS; MACROLIDES; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OXAZOLIDINONES; THIOACETAZONE; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 85008474067     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00993-2016     Document Type: Article

References (36)

1. World Health Organization (WHO). Global Tuberculosis Report 2015. Geneva, WHO, 2015.
2. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9, 153 patients. PLoS Med 2012;9:e1001300.
3. World Health Organization (WHO). Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva, WHO, 2011.
4. Dooley KE, Obuku EA, Durakovic N, et al. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis 2013;207:1352-1358.
5. Chang KC, Yew WW, Tam CM, et al. WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis. Antimicrob Agents Chemother 2013;57:4097-4104.
6. Winters N, Butler-Laporte G, Menzies D. Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment. Eur Respir J 2015;46:1461-1470.
7. Tyagi S, Ammerman NC, Li S, et al. Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. Proc Natl Acad Sci USA 2015;112:869-874.
8. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012;367:1508-1518.
9. Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J 2015;45:161-170.
10. Tang S, Yao L, Hao X, et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis 2015;60:1361-1367.
11. Dey T, Brigden G, Cox H, et al. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2013;68:284-293.
12. Gopal M, Padayatchi N, Metcalfe JZ, et al. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2013;17:1001-1007.
13. Stewart LA, Tierney JF. To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof 2002;25:76-97.
14. Simmonds MC, Higgins JP. Covariate heterogeneity in meta-analysis: criteria for deciding between metaregression and individual patient data. Stat Med 2007;26:2982-2999.
15. Ackçakir Y. Correlates of Treatment Outcomes of Multidrug-Resistant Tuberculosis (MDR-TB): a Systematic Review and Meta-Analysis. Montreal, McGill University; 2010. http://digitool.library.mcgill.ca/R/-?func=dbinjump-full&object-id=86914 Date last accessed: August 6, 2016. Date last updated: 2010.
16. Johnston JC, Shahidi NC, Sadatsafavi M, et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PloS One 2009;4:e6914.
17. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009;9:153-161.
18. Van Deun A, Salim MA, Das AP, et al. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004;8:560-567.
19. Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005;9:640-645.
20. Bastos ML, Hussain H, Weyer K, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis 2014;59:1364-1374.
21. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
22. Fox GJ, Benedetti A, Mitnick CD, et al. Propensity score-based approaches to confounding by indication in individual patient data meta-analysis: non-standardized treatment for multidrug resistant tuberculosis. PloS One 2016;11:e0151724.
23. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
24. Coca-Perraillon M, ed. Matching with Propensity Scores to Reduce Bias in Observational Studies. Proceedings of the NorthEast SAS Users Group Conference (NESUG), Philadelphia, PA; 2006.
25. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399-424.
26. Austin PC. The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med 2013;32:2837-2849.
27. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a nonrandomized control group. Stat Med 1998;17:2265-2281.
28. Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol 2001;54:387-398.
29. Jackson D, White IR, Riley RD. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med 2012;31:3805-3820.
30. Stewart LA, Clarke M, Rovers M, et al. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD statement. JAMA 2015;313:1657-1665.
31. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
32. Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005;365:318-326.
33. World Health Organization (WHO). WHO Treatment Guidelines for Drug-Resistant Tuberculosis: 2016 Update. Geneva, WHO, 2016.
34. Padayatchi N, Gopal M, Naidoo R, et al. Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study. J Antimicrob Chemother 2014;69:3103-3107.
35. Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012;56:3271-3276.
36. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366:2151-2160.